David Krantz

Mr. David Krantz


Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
JSJiri Sonek
Jiri Sonek
DKDavid Krantz
David Krantz
JCJon Carmichael
Jon Carmichael
CDCathy Downing
Cathy Downing
KJKaren Jessup
Karen Jessup
DMDavid McKenna
David McKenna

11 October 2023 in Brain Stimulation
Verified
Journal Article
Open access
THTodd M. Hutton
Todd M. Hutton
SAScott T. Aaronson
Scott T. Aaronson
LCLinda L. Carpenter
Linda L. Carpenter
KPKenneth Pages
Kenneth Pages
DKDavid Krantz
David Krantz
HSHarold A. Sackeim
Harold A. Sackeim
The number of sessions in an acute TMS course for major depressive disorder (MDD) is greater than in the earlier randomized controlled trials. To compare clinical outcomes in groups that received differing numbers of TMS sessions. From a registry sample (N = 13,732), data were extracted for 7215 patients treated for MDD with PHQ-9 assessments before and after their TMS course. Groups were defined by number of acute course treatment sessions: 1-19 (N = 658), 20-29 (N = 616), 30-35 (N = 1375), 36 (N = 3591), 37-41 (N = 626), or >41 (N = 349) and compared in clinical outcomes at endpoint and at fixed intervals (after 10, 20, 30, and 36 sessions). The impact of additional treatments beyond 36 sessions was also examined. Groups that received fewer than 30 sessions had inferior endpoint outcomes than all other groups. PHQ-9 symptom reduction was greatest in the group that ended treatment at 36 sessions. The extended treatment groups (>36 sessions) differed from all other groups by manifesting less antidepressant response early in the course and had a slower but steady rate of improvement over time. Extending treatment beyond 36 sessions was associated with further improvement without evidence of a plateau. In real-world practice, there are strong relations between the number of TMS sessions in a course and the magnitude of symptom reduction. Courses with less than 30 sessions are associated with diminished benefit. Patients with longer than standard courses typically show less initial improvement and a more gradual trajectory, but meaningful benefit accrues with treatment beyond 36 sessions.

15 October 2014 in Ultrasound in Obstetrics & Gynecology
Verified
Journal Article
Open access
PDF file
MEM. I. Evans
M. I. Evans
JSJ. D. Sonek
J. D. Sonek
THT. W. Hallahan
T. W. Hallahan
DKDavid Krantz
David Krantz
Objectives: To determine whether implementation of primary cell‐free fetal DNA (cffDNA) screening would be cost‐effective in the USA and to evaluate potential lower‐cost alternatives.Methods: Three strategies to screen for trisomy 21 were evaluated using decision tree analysis: 1) a primary strategy in which cffDNA screening was offered to all patients, 2) a contingent strategy in which cffDNA screening was offered only to patients who were high risk on traditional first‐trimester screening and 3) a hybrid strategy in which cffDNA screening was offered to all patients ≥ 35 years of age and only to patients < 35 years who were high risk after first‐trimester screening. Four traditional screening protocols were evaluated, each assessing nuchal translucency (NT) and pregnancy‐associated plasma protein‐A (PAPP‐A) along with either free or total beta‐human chorionic gonadotropin (β‐hCG), with or without nasal bone (NB) assessment.Results: Utilizing a primary cffDNA screening strategy, the cost per patient was 1017 US$. With a traditional screening protocol using free β‐hCG, PAPP‐A and NT assessment as part of a hybrid screening strategy, a contingent strategy with a 1/300 cut‐off and a contingent strategy with a 1/1000 cut‐off, the cost per patient was 474, 430 and 409 US$, respectively. Findings were similar using the other traditional screening protocols. Marginal cost per viable case detected for the primary screening strategy as compared to the other strategies was 3–16 times greater than the cost of care for a missed case.Conclusions: Primary cffDNA screening is not currently a cost‐effective strategy. The contingent strategy was the lowest‐cost alternative, especially with a risk cut‐off of 1/1000. The hybrid strategy, although less costly than primary cffDNA screening, was more costly than the contingent strategy. © 2014 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of the International Society of Ultrasound in Obstetrics and Gynecology.

1 September 2021 in American Journal of Obstetrics & Gynecology MFM
Verified
Journal Article
Closed access
MGMoti Gulersen
Moti Gulersen
Eran BornsteinEran Bornstein
Eran Bornstein
ADAlixandra Domney
Alixandra Domney
MBMatthew Blitz
Matthew Blitz
TRTimothy J. Rafael
Timothy J. Rafael
BRBurton Rochelson
Burton Rochelson

18 July 2017 in Prenatal Diagnosis
Verified
Journal Article
Open access
PDF file
JCJonathan B. Carmichael
Jonathan B. Carmichael
HLHsiao-Pin Liu
Hsiao-Pin Liu
DJDavid Janik
David Janik
THTerrence W. Hallahan
Terrence W. Hallahan
KNKypros Herodotos Nicolaides
Kypros Herodotos Nicolaides
DKDavid Krantz
David Krantz
The study aims to determine the performance of a five (5) serum marker plus ultrasound screening protocol for T21, T18 and T13. Specimens from 331 unaffected, 34 T21, 19 T18 and 8 T13 cases were analyzed for free Beta human chorionic gonadotropin, pregnancy-associated plasma protein A, alpha-fetoprotein, placental growth factor and dimeric inhibin A. Gaussian distributions of multiples of the median values were used to estimate modeled false positive and detection rates (DR). For T21, at a 1/300 risk cut-off, DR of screening with all five serum markers along with nuchal translucency and nasal bone was 98% at a 1.2% false positive rate (FPR). Using a 1/1000 cut-off, the DR was 99% with a 2.6% FPR. For T18/13 with free Beta human chorionic gonadotropin, pregnancy-associated plasma protein A, placental growth factor and nuchal translucency at a 1/150 cut-off, DR was 95% at a 0.5% FPR while at a 1/500 risk cut-off, DR was 97% at a 1.2% FPR. An expanded conventional screening test can achieve very high DRs with low FPRs. Such screening fits well with proposed contingency protocols utilizing cell-free DNA as a secondary or reflex but also provides the advantages of identification of pregnancies at risk for other adverse outcomes such as early-onset preeclampsia. © 2017 Eurofins NTD, LLC. Prenatal Diagnosis published by John Wiley & Sons, Ltd.

1 August 2000 in Obstetrics & Gynecology
Verified
Journal Article
Closed access
DKDavid Krantz
David Krantz
THTerrence W. Hallahan
Terrence W. Hallahan
FOFrancesco Orlandi
Francesco Orlandi
PBPhilip Buchanan
Philip Buchanan
JLJohn W. Larsen
John W. Larsen
JMJames N. Macri
James N. Macri